Globeflex Capital’s Gyre Therapeutics GYRE Stock Holding History

Globeflex Capital’s Portfolio GYRE Stock Details GYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-9,483	Closed	-$417K	–	491
2020 Q2	$417K	Buy	+9,483	New	+$445K	0.11%	308

Other funds holding GYRE

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Globeflex Capital's GYRE Position: Q3 2020 in Review

Globeflex Capital sold out of Gyre Therapeutics (GYRE) in Q3 2020, closing a stake of 9,483 shares — an estimated $417K sold.

Globeflex Capital first reported a position in GYRE in Q2 2020 and held it in 1 quarter. The position peaked at $417K in Q2 2020. 78 funds tracked by Wall St. Rank hold GYRE as of Q3 2020.

Globeflex Capital reported no remaining Gyre Therapeutics position as of Q3 2020 after selling out during the quarter.
Globeflex Capital sold 9,483 Gyre Therapeutics shares in Q3 2020, an estimated $417K.
Globeflex Capital first reported a position in Gyre Therapeutics in Q2 2020 and held it in 1 quarter.
Globeflex Capital's Gyre Therapeutics position peaked at $417K in Q2 2020.
78 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q3 2020.

Based on Globeflex Capital's 13F filing for Q3 2020, filed 13 Nov 2020.